JMP Securities Downgrades Vitae Pharmaceuticals (VTAE) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
Buy Vitae Pharmaceuticals (VTAE) on Weakness, Piper Jaffray Says
June 30, 2015 7:07 AM EDTPiper Jaffray analyst Edward Tenthoff lowered his price target on Vitae Pharmaceuticals (NASDAQ: VTAE) to $20.50 (from $23.00) after its Boehringer Ingelheim partnered diabetes drug VTP-34072 failed in combination with metformin in a Phase II trial. However, the firm is maintaining an Overweight... More
Wedbush Maintains Bullish View on Vitae Pharma (VTAE) Even as VTP-34072 for Diabetes Essentially Shelved
June 29, 2015 12:42 PM EDTWedbush analyst Liana Moussatos trimmed her price target on Vitae Pharmaceuticals (NASDAQ: VTAE) to $20.00 (from $21.00) after VTP-34072 for diabetes is essentially shelved. However, the firm maintained an Outperform rating.
"Even though the program is not formally discontinued and data from the... More
Vitae Pharmaceuticals (VTAE) Announces BI187004/VTP-34072 Phase 2 Missed Primary Efficacy Endpoint
June 29, 2015 6:33 AM EDTVitae Pharmaceuticals (NASDAQ: VTAE) announced top-line clinical efficacy results from the metformin arm of an ongoing Phase 2 proof-of-concept clinical trial of BI187004/VTP-34072 in the treatment of overweight type 2 diabetic patients. BI187004/VTP-34072 is a potential first-in-class 11-hydroxysteroid dehydrogenase type 1 (11 HSD1) inhibitor that was discovered by... More
